These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38789398)

  • 41. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
    Underwood MR; Johns BA; Sato A; Martin JN; Deeks SG; Fujiwara T
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):297-301. PubMed ID: 22878423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
    Dekker JG; Klaver B; Berkhout B; Das AT
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
    [No Abstract]   [Full Text] [Related]  

  • 45. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
    Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
    Zhang WW; Cheung PK; Oliveira N; Robbins MA; Harrigan PR; Shahid A
    J Infect Dis; 2018 Oct; 218(11):1773-1776. PubMed ID: 30010985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
    Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
    AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
    Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
    [No Abstract]   [Full Text] [Related]  

  • 53. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.
    Smith SJ; Ferris A; Zhao X; Pauly G; Schneider JP; Burke TR; Hughes SH
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.
    Ziegler RE; Desai BK; Jee JA; Gupton BF; Roper TD; Jamison TF
    Angew Chem Int Ed Engl; 2018 Jun; 57(24):7181-7185. PubMed ID: 29756689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
    Raffi F; Wainberg MA
    Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
    Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.
    Dekker JG; Klaver B; Berkhout B; Das AT
    J Virol; 2023 May; 97(5):e0036123. PubMed ID: 37125907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.